Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called latanoprost free acid (100ng/day) over a period of approximately 30 weeks”In the company’s words, NCT05333419 on ClinicalTrials.gov
- Tested for
- Open Angle Glaucoma, Ocular Hypertension
- Main trialPhase 1
- “This is an open label, single dose (100 ng/day) study to assess the safety, tolerability and biodegradation of the PA5436 Latanoprost FA SR Ocular Implant in adults who have OAG or OHT.”In the company’s words, NCT05333419 on ClinicalTrials.gov
Other drugs for Open Angle Glaucoma
- Bimatoprost ophthalmic 0.01% YSBPYS Life Science Co., Ltd. · Phase 3
- HUC3-637Huons Co., Ltd. · Phase 3
- Gen 2 Travoprost Intracameral ImplantGlaukos Corporation · Phase 3
- Product DNN.31.19.026Ache Laboratorios Farmaceuticos S.A. · Phase 3
- Citicoline eye drops 2%Omikron Italia S.r.l. · Phase 3
- Bimatoprost 0.01% OphthalmicAmneal Pharmaceuticals, LLC · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 12 Jun 2023 | Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026